<DOC>
	<DOCNO>NCT01626547</DOCNO>
	<brief_summary>The purpose study observe correction haemoglobin ( Hb ) level patient receive chemotherapy consequence solid tumour , malignant lymphoma multiple myeloma treat Retacrit™ .</brief_summary>
	<brief_title>Biosimilar Retacrit™ ( Epoetin Zeta ) Treatment Chemotherapy-Induced Symptomatic Anaemia Haematology Oncology</brief_title>
	<detailed_description>This non-interventional , descriptive , national , multi-site , longitudinal prospective observational study adult patient suffer cancer malignant blood disease whose chemotherapy treatment induce symptomatic anaemia treat Retacrit® correct haemoglobin level .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Patients age ≥18 year . Patients present chemotherapyinduced symptomatic anaemia . Patients suffer solid tumour , malignant lymphoma multiple myeloma develop symptomatic anaemia due chemotherapy . The patient may include regardless chemotherapy cycle ( first cycle last cycle ) Patients eligible epoetin alfa biosimilar treatment . Patients receive chemotherapy . Patients already include epoetin zeta study . Patients present contraindication epoetin zeta . Patients present hypersensitivity active substance excipients . The patient present erythroblastopenia , 'pure red cell aplasia ' ( PRCA ) . Patients uncontrolled hypertension . Patients receive adequate prophylaxis antithrombotic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>symptomatic anameia</keyword>
</DOC>